ClinicalTrials.gg

Program

belzutifan

Also written as “Belzutifan” and “Belzutifan 120mg”.

Its studies are mostly in Carcinoma, Renal Cell · Neoplasms · von Hippel-Lindau Disease · Pheochromocytoma · Breast Neoplasms, led by Merck.

Furthest: phase 3, since Dec 10, 201924 company-led studies, 15 open or runningNext primary completion: Feb 26, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck2415 open or runningphase 3since Dec 10, 2019Aug 3, 2016Feb 26, 2027phase 2 · NCT03634540

Also a collaborator on its studies: Eisai.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Aug 3, 2016.

  1. Oct 9, 2020Phase 3 study in Carcinoma, Renal CellNCT04586231 · 747 enrolled · United States, Argentina, Australia and more
  2. Nov 10, 20202 phase 2 studies in Carcinoma, Renal CellNCT04626518, NCT04626479
  3. Jan 29, 2021Phase 3 study in Carcinoma, Renal CellNCT04736706 · 1,688 enrolled · United States, Australia, Brazil and more
  4. Apr 7, 2021Phase 1 study in Carcinoma, Renal CellNCT04846920 · 29 enrolled · United States
  5. Jun 8, 2021Phase 2 study in PheochromocytomaNCT04924075 · 355 planned · United States, Australia, Canada and more
  6. Jul 16, 2021Phase 2 study in NeoplasmsNCT04976634 · 730 enrolled · United States, Australia, Belgium and more
  7. Aug 2, 20213 phase 1 studiesNCT04995484, NCT04994522, NCT05030506
  8. Feb 4, 2022Phase 3 study in Carcinoma, Renal CellNCT05239728 · 1,800 enrolled · United States, Australia, Brazil and more
  9. Jun 2, 2023Phase 3 study in Carcinoma, Renal CellNCT05899049 · 251 enrolled · China
  10. May 20, 2024Phase 2 study in Breast NeoplasmsNCT06428396 · 120 enrolled · United States, Argentina, Canada and more
  11. Mar 25, 2025Phase 1 study in HealthyNCT06903715 · 14 enrolled · United States
  12. Aug 12, 2025Phase 1 study in HealthyNCT07121959 · 14 enrolled · United States
  13. Feb 5, 2026Phase 3 study in von Hippel-Lindau DiseaseNCT07405164 · 450 planned · United States, Australia, Belgium and more
  14. Jul 8, 2026Phase 2 study in NeoplasmsNCT07700758 · 15 planned · United States, Belgium, Denmark and more

Ahead

  1. Feb 26, 2027Primary completion: phase 2 study in Carcinoma, Renal CellNCT03634540
  2. Mar 22, 2027Primary completion: phase 2 study in NeoplasmsNCT04976634
  3. Apr 29, 2027Primary completion: phase 2 study in von Hippel-Lindau DiseaseNCT03401788
  4. May 5, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06428396

TargetBeta

EPAS1 →read by rule
“Endothelial PAS domain-containing protein 1 inhibitor”ChEMBL 37, by rule

Other programs on EPAS1

ProgramCompanyFurthest phaseStudies
casdatifanruleArcus Biosciencesphase 39

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07700758Neoplasms · United States, Belgium, Denmark and more2RecruitingJan 2, 203415
NCT07405164von Hippel-Lindau Disease · United States, Australia, Belgium and more3RecruitingApr 22, 2034450
NCT07121959Healthy · United States1CompletedSep 13, 202514
NCT06903715Healthy · United States1CompletedMay 8, 202514
NCT06428396Breast Neoplasms · United States, Argentina, Canada and more2Active, not recruitingMay 5, 2027120
NCT05899049Carcinoma, Renal Cell · China3Active, not recruitingFeb 4, 2026251
NCT05239728Carcinoma, Renal Cell · United States, Australia, Brazil and more3Active, not recruitingOct 28, 20261,800
NCT05030506Carcinoma, Renal Cell · China1Active, not recruitingJun 30, 202745
NCT04995484Moderate Hepatic Impairment · United States1CompletedDec 25, 202317
NCT04994522Kidney Failure, Chronic · United States1CompletedApr 1, 202414
NCT04976634Neoplasms · United States, Australia, Belgium and more2Active, not recruitingMar 22, 2027730
NCT04924075Pheochromocytoma · United States, Australia, Canada and more2RecruitingNov 18, 2032355
NCT04846920Carcinoma, Renal Cell · United States1CompletedApr 11, 202629
NCT04736706Carcinoma, Renal Cell · United States, Australia, Brazil and more3Active, not recruitingFeb 4, 20261,688
NCT04626518Carcinoma, Renal Cell · United States, Australia, Canada and more2CompletedJul 23, 2026263
NCT04626479Carcinoma, Renal Cell · United States, Australia, Canada and more2CompletedAug 10, 2026393
NCT04586231Carcinoma, Renal Cell · United States, Argentina, Australia and more3Active, not recruitingFeb 2, 2026747
NCT04489771Carcinoma, Renal Cell · United States, Australia, Belgium and more2CompletedFeb 10, 2023154
NCT04195750Carcinoma, Renal Cell · United States, Brazil, Canada and more3Active, not recruitingApr 15, 2024755
NCT03634540Carcinoma, Renal Cell · United States2Active, not recruitingFeb 26, 2027118
NCT03445169Healthy · United States1CompletedMay 26, 201816
NCT03401788von Hippel-Lindau Disease · United States, Denmark, France and more2Active, not recruitingApr 29, 202750
NCT02974738Carcinoma, Renal Cell1Active, not recruitingJan 12, 2018120
NCT02861573Metastatic Castration-Resistant Prostate Cancer2Active, not recruitingOct 22, 20271,200

How it is read

Names in the registry

  • “Belzutifan”, 23 entries
  • “Belzutifan 120mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.